4
1
↑4
↓0
—1
Evidence suggests MDMA mayincreaseOral health.
6 studies (5 claims)
Emerging evidence
Typical effective dose 1.6 (1.6–1.6) mgacross 1 dosed study
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| psychedelics, such as psilocybin and MDMA | No effect - offer an alternative avenue of therapy | many mental health disorders | Human | — | Not specified | The emerging role of psilocybin and MDMA in the treatment of mental illness.cited 33× |
| MDMA | Increases - may pose | a serious harm for health | Human | young and adult people | Not specified | Neurotoxicity of MDMA: Main effects and mechanisms.cited 36× |
| MDMA | Increases - approved | mental health indications | Human | Australia | Not mentioned | Expert recommendations for Germany's integration of psychedelic-assisted therapy.cited 1× |
| MDMA-AP | No effect - no overall differences in attitudes towards | attitudes of mental health professionals | Human | Psychiatrists, psychologists and MH researchers from across Australia | Not mentioned | Evaluating the attitudes of mental health professionals towards trials of MDMA: a randomised vignette trial.cited 1× |
| oral MDMA administration | Increases - positive | MDMA oral fluid test at proposed US Substance Abuse and Mental Health Services Administration cutoff (50 ng/mL) | Human | 29 healthy adults with histories of MDMA use | Low (1.0 mg/kg) and high (1.6 mg/kg) oral doses. | MDMA and metabolite disposition in expectorated oral fluid after controlled oral MDMA administration.cited 11× |